Predicting rates of cognitive and functional decline in Alzheimer’s disease and mild cognitive impairment
Our models use only routinely collected and easily accessible data, offering high translational potential. If implemented, our scalable, data-driven prognostic support tool could streamline clinical workflows, support personalised care planning, and provide PLWD and their families with greater clarity and reassurance.
Authors
- Chloe Walsh (ORCID: https://orcid.org/0000-0002-3091-4853)
- Nan Fletcher‐Lloyd (ORCID: https://orcid.org/0000-0003-2002-5945)
- Antigone Fogel
- Paresh Malhotra
- Mina Ryten
- Ramin Nilforooshan
Institutions
- Imperial College Healthcare NHS Trust (GB)
- University of Cambridge (GB)
- UK Dementia Research Institute (GB)
- Imperial College London (GB)
- Surrey and Borders Partnership NHS Foundation Trust (GB)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1038/s43856-026-01432-w
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- UK Research and Innovation
- Alzheimer's Society
- National Institute for Health and Care Research
- Royal Academy of Engineering
- Eisai
- Servier
- H. Lundbeck A/S
- IXICO
- UK Dementia Research Institute
- National Institutes of Health
- Genentech
- Canadian Institutes of Health Research
- Medical Research Council
- Engineering and Physical Sciences Research Council
- NIHR Imperial Biomedical Research Centre